Expand search. D. Rami Hannoush 5d · Edited Report this post Report Report. Rami Hannoush is the Chief Executive Officer (interim), President and a co-founder of EpiBiologics. D. Rami Hannoush is the co-founder, interim CEO and president of EpiBiologics. D. Rami N. Developing tool ligands that target individual LRP6 domains could help elucidate the mechanism of. Rami Hannoush, Ph. com . 1007/978-1-4939-9532-5_17 Abstract Wnts are lipid-modified proteins that regulate stem cell signaling via Frizzled receptors on the cell surface. and Jim Wells to the portfolio. CSB 243: Biotechnology and Development of Therapeutics (Autumn) Regeneration of the adult intestinal epithelium is mediated by a pool of cycling stem cells, which are located at the base of the crypt, that express leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5). rami@gene. ’s Post Rami Hannoush, Ph. … | 79 comments on LinkedInRami Hannoush, Ph. ’s Post Rami Hannoush, Ph. Back. … | 79 comments on LinkedInRami Hannoush, Ph. Wnt ligands are critical for tissue homeostasis and form a complex with LRP6 and frizzled coreceptors to initiate Wnt/β-catenin signaling. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…We would like to show you a description here but the site won’t allow us. D. Fatty acylation of proteins is a versatile co-translational or post-translational modification that plays a key role in human. Rami Hannoush: Franklin Berger — Eli Lilly — DCVC Bio . Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. On average, Rami Hannoush works for one company for 2 years 7 months. D. ’s Post Rami Hannoush, Ph. Rami Hannoush, Ph. The Hedgehog and Wnt signaling pathways in cancer. , South San Francisco, CA, USA. A summer 2021 meeting between fellow. , Partner at Mubadala Capital, and Dr. hannoush. Rami Hannoush, Ph. I had the pleasure to join Rob Faulkner and Soo Romanoff on a panel to talk about the #biotech. D. S. We cover his grad school/post-doc training in chemical biology, 15+ years as a group leader Genentech and. Rami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. The WNT-FZD (W i n gless/In t 1-F ri z zle d) signaling system has a prevalent role in physiology during adulthood. D. ’s Post Rami Hannoush, Ph. Scheme 2 S3 . This button displays the currently selected search type. ’s Post Rami Hannoush, Ph. D. Born on September 20th, 1976 (47 years old)Rami Hannoush, Ph. منشور Rami Hannoush, Ph. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. Rami Hannoush has been working as a General Partner | US Ventures for Mubadala for 456 days. D. 1021/ja903745s. Rami Hannoush, Ph. Hannoush. Congratulations to our own Rami Hannoush, Principal Scientist, Early Discovery Biochemistry, for being one of ten to receive the U. He also served as its founding Chief Scientific Officer and Chair of the Board of Directors since its inception. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 1mo Report this post Report Report. Genentech veteran Rami Hannoush, UCSF professor Jim Wells team up to score $50M for protein degradation startup EpiBiologics - San Francisco Business TimesThere are 8 professionals named "Rami D", who use LinkedIn to exchange information, ideas, and opportunities. Supplementary Text and Figures. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 3mo Edited Report this post At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it provides a blueprint that. D. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 10mo EditedGreat chat with Ron Leuty from San Francisco Business Times to share our story on building EpiBiologics #companybuilding #degradation | 37 Kommentare auf LinkedInIn an interview with BioPharma Dive: Biotech and Pharma news, our co-founders Jim Wells and Rami Hannoush discussed the company's origin and EpiBiologics' differentiated protein degradation approach. Aaron H Nile 1 , Susmith Mukund 2 , Karen Stanger 1 , Weiru Wang 2 , Rami N Hannoush 3 Affiliations 1 Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA 94080. 2017. Rami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. Rami Hannoush, Ph. At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…Rami Hannoush, Ph. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. … | 77 comments on LinkedInRami Hannoush, Ph. Great chat with Ron Leuty from San Francisco Business Times to share our story on building EpiBiologics #companybuilding #degradation | 28 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. “Jim and I have known each other for the past 15 years through Genentech collaborations. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Rami Hannoush, Ph. D. H. Baran . Lotte Simonsen, Novo Nordisk. D. ’s Post Rami Hannoush, Ph. The assay offers temporally resolved detection of Wnt-stimulated accumulation of beta-catenin, simultaneously detecting cell number, and it sheds light onto the kinetics of posttranslational. Rami N Hannoush is part of Stanford Profiles, official site for faculty, postdocs, students and staff information (Expertise, Bio, Research, Publications, and more). Rami Hannoush has 2 current jobs as General Partner at Mubadala Capital Ventures and Co-Founder at EpiBiologics. Marianne Mertens, Ph. , 1 DNA Way, South San Francisco, CA 94080, USA. D. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. Manage my profile. Headquarters Regions San Francisco Bay Area, Silicon Valley, West [email protected] N Hannoush, Ph. Vlieghe et al. Rami Hannoush, PhD. The company intends to use the funds to advance the lead program toward clinical development and drive additional programs into drug discovery. She is taking over from co-founder Rami Hannoush, who will step into an advisory role. Hannoush* and Natalia Arenas-Ramirez . Back. doi: 10. Rami Hannoush is a co-founder, President and interim CEO of EpiBiologics. D. He brings a unique blend of investment experience and deep drug discovery expertise to our. The Hannoush group is focused on developing pharmacological strategies for targeting proteins and protein – protein interactions that are important in disease, with the aim of developing novel therapeutics and at the same time advancing their understanding of cellular molecular mechanisms. This past Saturday, the Class of 2023…Biomarker interview with Rami Hannoush, Ph. com). In an interview with BioPharma Dive: Biotech and Pharma news, our co-founders Jim Wells and Rami Hannoush discussed the company's origin and EpiBiologics' differentiated protein degradation approach. Healthcare VC | Life sciences company creation. Rami Hannoush, Ph. Rami N. Question: Add details. D. They found a peptide that converts the caspase to its inactive state—the zymogen—and traps it there, a bit like a wheel clamp. Burns, Irina Krylova, Rami N. Rami Hannoush is a co-founder, President and interim CEO of EpiBiologics. D. ’s Post Rami Hannoush, Ph. D. Healthcare VC | Life sciences company creation. THE AURON TEAM A CULTURE OF INNOVATION. Rami Hannoush is a venture partner operating across San Diego and the San Francisco Bay Area. Burns, Irina N. October 7-10, 2018 | Emerging Data on the Role of Wnt Biology in Cancer | 4 WEDNESDAY, OCTOBER 10 7:15 am Breakfast 9:00 am SESSION 8: Emerging Applications for Wnt Signaling in CancerRami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. Electronic address: hannoush. D. D. Rami Hannoush, EpiBiologics is building a protein degradation platform that targets membrane and extracellular proteins. When expanded it provides a list of search options that will switch the search inputs to match the. D. It’s been a terrific two days at #jpm2023, meeting new talent and connecting with friends in pharma and the VC world. Clickable fatty acids coupled with in situ proximity ligation allow visualization of Wnt as it trafficks through the secretory pathway, defining roles for palmitoylation and glycosylation in. The American Peptide Society, APS, a nonprofit scientific and educational organization founded in 1990, provides a forum for advancing and promoting knowledge of the chemistry and biology of peptides. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. He is 48 year old. ’s Post Rami Hannoush, Ph. Expand search. D. Marianne Mertens, [email protected]. degree at McGill University. 05. Dr. Hannoush's 87 research works with 3,279 citations and 10,017 reads, including: Synthetic Multivalent Disulfide-Constrained Peptide Agonists Potentiate Wnt1/β-Catenin. Dynasore inhibits cell proliferation of OS in vitro. D. Rami Hannoush, Ph. Rami Hannoush, PhDPrincipal Scientist & Group Leader at Genentech. PMID: 26080277 DOI: 10. 11mo Report this comment Report Report. , Partner at Apollo Healthcare Ventures, will join the Company as Board observers. Contents: Chemical Synthesis S2 . Drug Discov. D. We cover Rami's new role at. PMID: 30530496 PMCID: PMC6333880 Rami Hannoush, interim-CEO, said, “Since launching the company, the team at EpiBiologics has been able to further validate and industrialize the EpiTAC platform, creating a fit-for-purpose atlas of degraders. ’s Post Rami Hannoush, Ph. D. Stablix is pioneering an entirely new field of targeted deubiquitination therapeutics (TDT) to bring transformative medicines to patients with unmet medical need. Rami Hannoush, Ph. Damtra, Masad (Supervisor) Abstract. Healthcare VC at Versant | Life sciences company creation | Former R&D leader, Genentech | Former CEO, EpiBiologics 3h Report this post. Inventors: Eric Bourhis, Tim Cao, Rick Carano, Andrea Cochran, Mike Costa, Venita DeAlmeida, James Ernst, Yan Gong, Rami Hannoush, Paul Polakis, Bonnee Rubinfeld, Mark Solloway, Yan Wu METHODS AND COMPOSITIONS FOR MODULATING THE Wnt PATHWAY Protein palmitoylation plays diverse roles in regulating the trafficking, stability, and activity of cellular proteins. D. D. Patrick Sexton, Monash University. The design of clickable fatty acid probes is based on the introduction of a small chemical tag (alkyne or azide) at the ω or methyl end of the fatty acid (Figure 2). Rami N. “We would like to thank Rami Hannoush for his leadership as co-founder and interim CEO and look forward to an exciting next stage of growth for EpiBiologics under Ann’s leadership. According to LinkedIn Rami Hannoush started working on 2006, then the employee has changed 9 companies and 12 jobs. D. Hannoush joined the Early Discovery Biochemistry department at Genentech in 2006 after completing his postdoctoral fellowship at Harvard and his Ph. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Rami Hannoush, Ph. Hannoush, Rami Nabil; Contributors. Human OS cell lines (MNNG/HOS, MG-63, and U2-OS) were treated with increasing concentrations of dynasore or cisplatin, and then the cell. 2015. Mr. Joel P. Leading strategies for expediting R&D and improving CMC efficiency. Hannoush joined the Early Discovery Biochemistry department at Genentech in 2006 after completing his postdoctoral fellowship at Harvard and his Ph. Human OS cell lines (MNNG/HOS, MG-63, and U2-OS) were treated with increasing concentrations of dynasore or cisplatin, and then the cell. , as Chief Data Officer,. From a previous marriage, he has a three-year-old son. The authors declare no competing financial interests. D. D. The . The small size of the chemical tag is meant to minimize interference with fatty acyltransferase substrate recognition and catalytic efficiency (Hannoush, 2015, Hannoush and Arenas-Ramirez, 2009). EpiBiologics’s CEO is Rami Hannoush Who are EpiBiologics key employees? Some of EpiBiologics key employees are Craig Lichtenstein Where is EpiBiologics located? EpiBiologics’s headquarters are located at 1900 Alameda De Las Pulgas Ste 250, San Mateo, California, 94403, United States How do I contact. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Biography. Rami Hannoush’s Post Rami Hannoush General Partner, Mubadala Capital | Healthcare VC | Life sciences company creation 4d Report this post. Expand search. D. D. ’s Post Rami Hannoush, Ph. Rami Hannoush, Ph. Less time bookkeeping means more time to pursue your. San Mateo, CA. D. Auron was founded by a world class team of physicians and scientists with proven expertise in bringing effective differentiation therapies to patients. Founded in 2022 and led by CEO Dr. D. PMID: 29290622 DOI: 10. Professor Nagy Habib is Head of Surgery at the Hammersmith Campus of Imperial College London and also a serial founder and entrepreneur of life sciences ventures. A fascinating approach to degrade membrane proteins/receptors. He brings a unique blend of investment experience and deep drug discovery expertise to our company creation efforts. This button displays the currently selected search type. D. See the complete. Yet, how different Wnts achieve various levels of signaling activation through distinct domains on LRP6 remains [email protected]@gene. Rami Hannoush serves as Venture Partner at Versant Ventures. D. rami@gene. D. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. The lipid-binding groove exhibits flexibility and spans both monomers,. D. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. com; PMID: 21964784 DOI: 10. D. Rami Hannoush has 2 current jobs as General Partner at Mubadala Capital Ventures and Co-Founder at EpiBiologics. Rami Hannoush, Ph. D. D. Benjamin Moore, and Dr. Hannoush has filed for patents to protect the following inventions. D. Congrats Juvena Therapeutics for the series A raise. D. The Frizzled (FZD) 7 receptor (FZD7) is enriched in LGR5 + intestinal stem cells and plays a. It has been an incredible journey building this company. D. Rami. When expanded it provides a list of search options that will switch the search inputs to match the. Healthcare VC | Life sciences company creation | Former R&D leader, GenentechComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Healthcare VC at Versant | Life sciences company creation | Former R&D leader, Genentech | Former CEO, EpiBiologics ٦ شهر الإبلاغ عن هذا المنشور. Back. ’s Post Rami Hannoush, Ph. Unparalleled access to new data & case studies from globally recognized speakers across the entire landscape of oligonucleotides, peptides, mRNA, genome. DOI: 10. Expand search. … | 79 تعليقات على LinkedInNatalia Arenas-Ramirez's 3 research works with 164 citations and 145 reads, including: Membrane targeting of palmitoylated Wnt and Hedgehog revealed by chemical probesgeneral partner at GV. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Targeting the destruction of proteins, Peninsula biotech EpiBiologics raises $50M. Expand search. Hannoush include Harvard University & Scripps Research Institute. Epub 2021 Dec 10. When expanded it provides a list of search options that will switch the search inputs to match the. D. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. ’s Post Rami Hannoush, Ph. His current role includes leading interdisciplinary teams in lead discovery and research biology, with the overarching goal of developing therapeutics for the. Department of Protein Engineering, Genentech, Inc. He also served as its founding Chief Scientific Read More View. Last Funding Type Series A. , Partner at Mubadala Capital, and Dr. Founded in 2022 and led by CEO Dr. Search for more papers by this author Speakers – APS 2022. D. Conference Description. Sponsors and Exhibitors. Read top stories published by MubadalaVentures. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Related to: Rana Hannoush, 42. com. , Partner at Mubadala Capital, and Dr. Rami Hannoush, Ph. Hannoush [email protected] Department of Early Discovery Biochemistry, Genentech, Inc. D. Back. 4d Edited. D. , Partner at Apollo Health Ventures, will join the Company as Board observers. 4 the Department of Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, and hannoush. Lee-Karlon served as. D. Marianne Mertens: Show More . Schneider, National Cancer Institute – Center for Cancer Research. ’s Post Rami Hannoush, Ph. Rami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. Previous affiliations of Rami N. Its proprietary EpiTAC platform is a. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. PMID: 24292069 DOI: 10. rami@gene. D. D. -based biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular. Skip to main content Due to a planned power outage on Friday, 1/14, between 8am. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Aaron H Nile & Rami N Hannoush* Wnt proteins are critical regulators of signaling networks during embryonic development and in adult tissue homeostasis. It is tightly controlled by a set of enzymes which catalyze the covalent attachment of fatty. I am thankful for the LPs, founders, CEOs, team members who have remained steadfast partners over the years in using advanced technology to build a better… | 13 comments on LinkedInRami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. We cover Rami's new role at. Hannoush is a general partner at Mubadala Capital, the financial investment arm of the Sovereign Wealth Fund Mubadala. D. 3 Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA 94080; hannoush. Rami Hannoush, EpiBiologics is building a protein degradation platform that targets membrane and extracellular proteins. D. com. The author has contributed to research in topics: Wnt signaling pathway & Frizzled. President’s Welcome. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Rami Hannoush: Chemical tools to perturb and image Wnt signaling: Danica Galonic Fujimori: 3/15/12: Harmit Malik, Fred Hutchinson Cancer Center: Genetic conflicts: the usual suspects and beyond: John Gross: 4/5/12: Ian Wilson, Scripps: Broad neutralization of HIV and influenza viruses: Bob Stroud:It started with a cup of coffee and a slow burning desire to go early and long in the biotech creation business. Rami N. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 7mo Report this post What are some of the factors that contribute to aging? And could we identify the specific mechanisms by which these factors impair tissue regeneration?Rami Hannoush, Ph. D. rami@gene. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Our group described u-alkyne fatty acids of various chain lengths (C10, C11, C13, C14, C16, and C18, with the alkyne group at the u position) (Figure 2) and showed the Wrapping up a 15-year discovery stint at Genentech back in the summer of 2021, Rami Hannoush was treated to a caffeine-fueled review of the latest work UCSF’s Jim Wells had been doing on protein degradation — one of the hottest fields in drug development. Biomarker interview with Rami Hannoush, Ph. Rami Hannoush, Ph. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. D. Lawyers - Get Listed Now! Get a free. Determination of binding interactions between lipid-modified Wnt. ’s Post Rami Hannoush, Ph. Phone and address: 35 28Th Ave #300, San Mateo, CA 94403. EpiBiologics Co-Founder. Congrats Cameron! Like Reply 1 Reaction. Rami Hannoush. Rami N Hannoush Adjunct Professor, Chemical and Systems Biology Operations Print Profile Email Profile Bio Bio Professional Contact. Hannoush is an academic researcher from Genentech. 025. degree at. Founders James Wells, Rami Hannoush. Rami Hannoush 7mo Report this post 2021 Innovative Medicines Fifty new drugs were FDA approved that help improve the health of patients with unmet medical needs and protect. D. ’s Post Rami Hannoush, Ph. D. D. Rami N Hannoush, Ph. Rami Hannoush, EpiBiologics is building a protein degradation platform that targets membrane and extracellular [email protected]. Its proprietary EpiTAC platform is a. cbpa. Jobs. D. Additional Details: 1000 Ask Question Find a Lawyer. Hannoush [email protected] Department of Early Discovery Biochemistry, Genentech, Inc. D. Healthcare VC at Versant | Life sciences company creation | Former R&D leader, Genentech | Former CEO, EpiBiologics 3h Report this post. com. Back. Rami Hannoush, Ph. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 6mo Edited Report this post. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. Hannoush, 5Wayne J. , San Francisco, California, USA. Chief Operating Officer (650) -. Rami Hannoush General Partner, Mubadala Capital | Life sciences company creation | Chief Scientific Officer 1y EditedRami Hannoush, Ph. PMID: 29632413 DOI: 10. Rami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO). com. S. D. “Dysregulation of normal cellular differentiation processes can alter normal cell biology leading to tumor formation and progression,” said Dr. BSMB Spring meeting 2022: "Interactions between Lipids/derivatives and the ECM: pre-clinical and clinical relevance" Registration for BSMB members is FREE, £10 and £30 respectively for student. He brings a unique blend of investment experience and deep drug discovery expertise to our company. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO). Rami Hannoush, Ph. ’s Post Rami Hannoush, Ph. Hannoush joined the Early Discovery Biochemistry department at Genentech in 2006 after completing his postdoctoral fellowship at Harvard and his Ph. Gemma met Rami in 2011 when she was just starting out on the reality show The Only Way Is Essex. D. Symposium Sponsors. "To our knowledge, no one has identified ligands that bind to the zymogen," said senior author Rami Hannoush, Genentech, South San Francisco, California. View the profiles of professionals named. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Scroll Top. ’s Post Rami Hannoush, Ph. D. ’s Post Rami Hannoush, Ph. D. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 5mo Report this post Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Rami Hannoush, Ph. Beachy. … | 80 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Rami Hannoush’s Post. . Rami Hannoush, Ph. ’s Post Rami Hannoush, Ph. THE AURON TEAM A CULTURE OF INNOVATION. degree at McGill University. D. edu - Homepage. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. Jennifer Stockdill, Wayne State. Rami N. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Rami Hannoush 7mo Report this post 2021 Innovative Medicines Fifty new drugs were FDA approved that help improve the health of patients with unmet medical needs and protect. Healthcare VC at Versant | Life sciences company creation | Former R&D leader, Genentech | Former CEO, EpiBiologics 1y. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Number of Current Jobs 2. , for the launch of [email protected]. Rami Hannoush, Ph. … | 77 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform.